CVS Health (CVS) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $1.19 per share a year ago.
CVS Health (NYSE: CVS) delivered a solid revenue beat in Q4 2025, though adjusted earnings declined year-over-year despite exceeding Wall Street expectations.
CVS Health earnings came in ahead of analyst forecasts but the company is concerned about Medicare rates.
The healthcare giant saw its revenue jump 8% in the fourth quarter
CVS Health reported earnings that beat analysts' expectations and kept its 2026 profit guidance unchanged, results that may soothe investors spooked by continued turmoil in the health-insurance sector.
Besides Wall Street's top-and-bottom-line estimates for CVS Health (CVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
The latest trading day saw CVS Health (CVS) settling at $75.24, representing a -2.07% change from its previous close.
CVS Health may report higher Q4 revenues, led by prescription growth and expanded pharmacy operations.
CVS Health remains well-positioned despite a sector-wide selloff after disappointing Medicare rate increases and UnitedHealth's outlook. CVS's early restructuring, cost cuts, and reduced Medicare exposure have prepared it better than peers for current industry headwinds. At 10–11x forward earnings, CVS trades at a discount to peers, with potential for multiple expansion if execution continues.
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Health (CVS) closed the most recent trading day at $74.03, moving +2.82% from the previous trading session.